European Journal of Cancer, Supplement

Aims & Scope

EJC Supplements is an open access companion journal to the European Journal of Cancer.

As an open access journal, all published articles are subject to an Article Publication Fee.

Immediately upon publication, all articles in EJC Supplements are made openly available through the journal's websites.

EJC Supplements will consider for publication the proceedings of scientific symposia, commissioned thematic issues, and collections of invited articles on preclinical and basic cancer research, translational oncology, clinical oncology and cancer epidemiology and prevention.

Authors considering the publication of a supplement in EJC Supplements are requested to contact the Editorial Office of the EJC to discuss their proposal with the Editor-in-Chief.

EJC Supplements is an official journal of the European Organisation for Research and Treatment of Cancer (EORTC), the European CanCer Organisation (ECCO) and the European Society of Mastology (EUSOMA).

Metrics & Ranking

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Directory of Open Access Journals (DOAJ)
• Embase

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Biochemistry, Genetics and Molecular Biology and Medicine, designed to support cutting-edge academic discovery.

Licensing & Copyright

This journal operates under an Open Access model. Articles are freely accessible to the public immediately upon publication. The content is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing users to share and adapt the work with proper attribution.

Copyright remains with the author(s), and no permission is required for non-commercial use, provided the original source is cited.

Policy Links

This section provides access to essential policy documents, guidelines, and resources related to the journal’s publication and submission processes.

• Aims scope
• Homepage
• Oa statement
• Author instructions
• License terms
• Review url
• Board url
• Copyright url
• Plagiarism url
• Preservation url
• Apc url
• License

Plagiarism Policy

This journal follows a plagiarism policy. All submitted manuscripts are screened using reliable plagiarism detection software to ensure originality and academic integrity. Authors are responsible for proper citation and acknowledgment of all sources, and any form of plagiarism, including self-plagiarism, will not be tolerated.

For more details, please refer to our official: Plagiarism Policy.

APC Details

The journal’s Article Processing Charge (APC) policies support open access publishing in Biochemistry, Genetics and Molecular Biology and Medicine, ensuring accessibility and quality in research dissemination.

This journal requires an Article Processing Charge (APC) to support open access publishing, covering peer review, editing, and distribution. The current APC is 3,000.00 USD. Learn more.

Explore journals without APCs for alternative publishing options.

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Electrochemotherapy – An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study

  Citation: 728

  Authors: Michel, Gregor, Jean Rémi, Julie, Christopher G., Marko, Valérie, Poul F., John O., Damijan, Ivan, Snezna M., Maja, Nassim, Declan M., Zvonimir, Caroline, Gerald C., Lluis M.

• Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes

  Citation: 476

  Authors: Lluis M., Julie, Gregor, Christopher G., Jean-Rémi, Valérie, Poul F., Z., Gerald C., Michel

• Melanoma epidemiology, biology and prognosis

  Citation: 202

  Authors: Z., N., J.

• Beyond treatment – Psychosocial and behavioural issues in cancer survivorship research and practice

  Citation: 185

  Authors: Neil K., Vittorio, Ollie, Joachim, Christoffer, Susanne O., Irma M., Kevin D., Catherine M., Anja, Angela, Lonneke V.

• Sexual dysfunction and infertility as late effects of cancer treatment

  Citation: 181

  Authors: Leslie R., Marleen, Eleonora, Carien, Eric, Cecilie E.

• Bases and rationale of the electrochemotherapy

  Citation: 152

  Authors: L.M.

• Nanoparticle albumin-bound (nabâ„¢)-paclitaxel: improving efficacy and tolerability by targeted drug delivery in metastatic breast cancer

  Citation: 126

  Authors: Javier, Cristina

• Importance of tumour coverage by sufficiently high local electric field for effective electrochemotherapy

  Citation: 123

  Authors: Damijan, Selma, Gorazd, Natasa

• Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors

  Citation: 122

  Authors: Manuela

• Cardiovascular disease after cancer therapy

  Citation: 118

  Authors: Berthe M.P., Elizabeth C., Janine, Thomas M., Maja V., Lena, Conny, Sarah C.